Brian Del Rosario

Brian Del Rosario

Auto-generated profile, based on publicly available information

Brian Del Rosario

Johnson & Johnson 2 Therapeutics Discovery Springhouse, Pennsylvania

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in eLife
Verified
Journal Article
Open access
BRBrian C Del Rosario
Brian C Del Rosario
AKAndrea J Kriz
Andrea J Kriz
ARAmanda M Del Rosario
Amanda M Del Rosario
AAAnthony Anselmo
Anthony Anselmo
CFChristopher J Fry
Christopher J Fry
JLJeannie T Lee
Jeannie T Lee
The zinc finger CCCTC-binding protein (CTCF) carries out many functions in the cell. Although previous studies sought to explain CTCF multivalency based on sequence composition of binding sites, few examined how CTCF post-translational modification (PTM) could contribute to function. Here, we performed CTCF mass spectrometry, identified a novel phosphorylation site at Serine 224 (Ser224-P), and demonstrate that phosphorylation is carried out by Polo-like kinase 1 (PLK1). CTCF Ser224-P is chromatin-associated, mapping to at least a subset of known CTCF sites. CTCF Ser224-P accumulates during the G2/M transition of the cell cycle and is enriched at pericentric regions. The phospho-obviation mutant, S224A, appeared normal. However, the phospho-mimic mutant, S224E, is detrimental to mouse embryonic stem cell colonies. While ploidy and chromatin architecture appear unaffected, S224E mutants differentially express hundreds of genes, including p53 and p21. We have thus identified a new CTCF PTM and provided evidence of biological function.

27 March 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
KSKarine Smans
Karine Smans
TNThomas Nesspor
Thomas Nesspor
SBSabine De Breucker
Sabine De Breucker
EHErika van Heerde
Erika van Heerde
AVAnnemie Valckx
Annemie Valckx
PGPaul R. Gavine
Paul R. Gavine
Mesothelin (MSLN) is a cell membrane–anchored glycoprotein overexpressed in several cancers, including pancreatic cancer, ovarian cancer, and mesothelioma. MSLN is protease-cleaved at the membrane proximal region, releasing shed MSLN (sMSLN) into the tumor microenvironment, leaving behind a membrane-bound stub. sMSLN in the tumor microenvironment is hypothesized to create a “sink” that could limit tumor binding of MSLN-targeted anticancer therapies. We describe JNJ-79032421, a bispecific antibody (BsAb) targeting cluster of differentiation (CD) 3 on T cells and the membrane-restricted, non-shed region of full-length MSLN on cancer cells. Crystal structure analysis confirmed JNJ-79032421 binding to the membrane-restricted, non-shed C-terminal region of MSLN. Using Western blotting, enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS), and immunohistochemistry (IHC), elevated levels of sMSLN were detected in blood, serosal fluids, and tumor tissue of patients and tended to increase with MSLN tumor expression. Binding and cytotoxicity of JNJ-79032421 against cancer cell lines were unaffected by the presence of sMSLN. In cancer cell lines and cell line–derived and patient-derived xenograft mouse models, increasing levels of MSLN expression led to increased JNJ-79032421 potency. In contrast, MSLNxCD3 BsAbs, binding of which is non–membrane-restricted, demonstrated a loss of cytotoxicity in the presence of sMSLN. This “sink” effect was most pronounced for high-affinity non–membrane-restricted BsAbs. Increases in CD45+ and CD8+ T-cell infiltration, as well as CD8+ T-cell activation, observed in xenograft tumor tissues were time-dependent and JNJ-79032421 dose–dependent. Overall, these data suggest that JNJ-79032421 may offer meaningful clinical activity by avoiding binding to sMSLN.

2 October 2026
Verified
Other
Open access
KSKarine Smans
Karine Smans
TNThomas Nesspor
Thomas Nesspor
SBSabine De Breucker
Sabine De Breucker
EHErika van Heerde
Erika van Heerde
AVAnnemie Valckx
Annemie Valckx
PGPaul R. Gavine
Paul R. Gavine
JNJ-79032421 efficacy in xenograft models expressing low to high levels of MSLN. A, IHC was performed on xenograft tumors from CDX and PDX models [LXFA 289 (NSCLC), PAXF 1657 (pancreatic cancer), PRXF-MRI-H-1579 (prostate cancer), and LXFA 1041 (NSCLC)] with anti-MSLN antibody MNC3B30, which binds to the membrane-restricted region of MSLN and detects both cleaved C-terminus and full-length MSLN, but not sMSLN. Qualitative MSLN level (HI/MED/LO) assigned below the tumor model in parenthesis. Blue, cell nuclei (hematoxylin); brown, MSLN; magnification bar = 100 µm. B, Mean tumor volumes ±SEM over time in CDX models. Tumor cells were implanted on day 0. Mice were humanized with T cells (as indicated by down triangle) on the day of randomization, and treatment was initiated 1 day after T-cell implantation. For OVCAR-8 and OVCAR-8 K1/C8 studies, mice were treated intraperitoneally twice weekly for 3 weeks with JNJ-79032421 at 0.1 and 0.01 mg/kg and MNC3B232 at 0.1 mg/kg. For SK-OV-3, mice were treated intraperitoneally twice weekly for 4 weeks with 0.1, 0.5, and 2.5 mg/kg JNJ-79032421 and 0.1 mg/kg MNC3B232. The dosing period is indicated by the bar below the X-axis. *Denotes significant difference (P ≤ 0.05) of the JNJ-79032421 or MNC3B232 treatment group compared with the control (DPBS) group. C, Mean tumor volumes ±SEM over time upon treatment of JNJ-79032421 in PDX mouse models. Tumor cells were implanted on day 0. Mice were humanized with T cells (as indicated by down green triangle) on the day of randomization, and treatment was initiated 1 day after T-cell implantation. Mice were treated intraperitoneally twice weekly for 3 weeks on days 19, 22, 26, 29, 33, and 36 (LXFA 289 MSLNHI+ and PRXF-MRI-H 1579 MSLNMED+) and on days 18, 21, 25, 28, 32, and 35 (PAXF 1657 MSLNMED+/HI+ and LXFA 1041 MSLNMED+/LO+). The dosing period is indicated by the bar below the X-axis. *Denotes significant difference (P ≤ 0.05) of JNJ-79032421 treatment groups compared with the DPBS group (LXFA 289, PRXF-MRI-H 1579, and LXFA 1041) or between groups treated with nullxCD3 and JNJ-79032421 (PAXF 1657). JNJ-79032421 at 0.1 mg/kg resulted in >100% ΔTGI of LXFA 289, PRXF-MRI-H 1579, and LXFA 1041 tumors and 69% ΔTGI of PAXF 1657 tumors with greater activity seen at higher doses. Levels of MSLN expression assigned based on IHC in A.

2 October 2026
Verified
Other
Open access
KSKarine Smans
Karine Smans
TNThomas Nesspor
Thomas Nesspor
SBSabine De Breucker
Sabine De Breucker
EHErika van Heerde
Erika van Heerde
AVAnnemie Valckx
Annemie Valckx
PGPaul R. Gavine
Paul R. Gavine
Quantification of (A) sMSLN in healthy and cancer sera, (B) sMSLN in serosal fluids, (C) full-length MSLN and sMSLN in CDXs and PDXs, and (D) full-length MSLN and sMSLN in NSCLC adenocarcinoma tumors. sMSLN levels were evaluated by ELISA in (A) serum samples from patients with cancer and healthy controls and (B) ovarian cancer ascites and lung cancer pleural effusions from patients with cancer. Means (±SD) are graphed; dashed horizontal lines denote the level of sMSLN in healthy-donor serum. C, MSLN levels in PDXs were determined by Western blot analysis using a rabbit anti-human MSLN antibody detecting both FL-MSLN and sMSLN. Samples were treated without or with PNGase, enabling SDS-PAGE resolution between FL-MSLN and sMSLN. Representative samples shown. Respective order of PDX models on blot: LXFA 1041 (#19), LXF 1125 (#20), OVXF 1320 (#6), OVXF 1993 (#7), PAXF 1994 (#13), PAXF 1997 (#14), and PXF 1118 (#75). D, FL-MSLN and sMSLN in 21 NSCLC adenocarcinoma tissues were quantified by Western blot analysis using a rabbit anti-human MSLN antibody detecting both FL-MSLN and sMSLN. Deglycos., deglycosylated; FL-MSLN, full-length mesothelin; Id, identification; MPM, malignant pleural mesothelioma; NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer; WB, Western blot.

2 October 2026
Verified
Other
Open access
PDF file
KSKarine Smans
Karine Smans
TNThomas Nesspor
Thomas Nesspor
SBSabine De Breucker
Sabine De Breucker
EHErika van Heerde
Erika van Heerde
AVAnnemie Valckx
Annemie Valckx
PGPaul R. Gavine
Paul R. Gavine
Table S1 provides the heavy and light variable chain sequence information for MSLN and CD3 antibodies used

2 October 2026
Verified
Other
Open access
PDF file
KSKarine Smans
Karine Smans
TNThomas Nesspor
Thomas Nesspor
SBSabine De Breucker
Sabine De Breucker
EHErika van Heerde
Erika van Heerde
AVAnnemie Valckx
Annemie Valckx
PGPaul R. Gavine
Paul R. Gavine
Table S3 summarizes the fold change of geomean killing EC50 values (with sMSLN versus without sMSLN) for mrMSLNxCD3 and nmrMSLNxCD3 BsAbs